JP2020517272A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517272A5
JP2020517272A5 JP2019557431A JP2019557431A JP2020517272A5 JP 2020517272 A5 JP2020517272 A5 JP 2020517272A5 JP 2019557431 A JP2019557431 A JP 2019557431A JP 2019557431 A JP2019557431 A JP 2019557431A JP 2020517272 A5 JP2020517272 A5 JP 2020517272A5
Authority
JP
Japan
Prior art keywords
recombinant phagemid
genome
particle
particles
expression cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019557431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517272A (ja
JP7671483B2 (ja
Filing date
Publication date
Priority claimed from GBGB1706451.0A external-priority patent/GB201706451D0/en
Application filed filed Critical
Publication of JP2020517272A publication Critical patent/JP2020517272A/ja
Publication of JP2020517272A5 publication Critical patent/JP2020517272A5/ja
Application granted granted Critical
Publication of JP7671483B2 publication Critical patent/JP7671483B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019557431A 2017-04-24 2018-04-24 癌の治療 Active JP7671483B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1706451.0A GB201706451D0 (en) 2017-04-24 2017-04-24 Cancer treatment
GB1706451.0 2017-04-24
PCT/GB2018/051070 WO2018197859A1 (en) 2017-04-24 2018-04-24 Cancer treatment

Publications (3)

Publication Number Publication Date
JP2020517272A JP2020517272A (ja) 2020-06-18
JP2020517272A5 true JP2020517272A5 (https=) 2021-07-29
JP7671483B2 JP7671483B2 (ja) 2025-05-02

Family

ID=58795775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557431A Active JP7671483B2 (ja) 2017-04-24 2018-04-24 癌の治療

Country Status (7)

Country Link
US (2) US11820792B2 (https=)
EP (1) EP3615562A1 (https=)
JP (1) JP7671483B2 (https=)
CN (1) CN110546253A (https=)
CA (1) CA3061422A1 (https=)
GB (1) GB201706451D0 (https=)
WO (1) WO2018197859A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
GB201519303D0 (en) 2015-11-02 2015-12-16 Imp Innovations Ltd Phagemid vector
GB201706451D0 (en) 2017-04-24 2017-06-07 Imp Innovations Ltd Cancer treatment
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
MY199770A (en) 2018-11-14 2023-11-22 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t cells
CA3223292A1 (en) * 2021-06-25 2022-12-29 Laura Van Lieshout Adeno-associated virus packaging systems
EP4649161A1 (en) * 2023-01-10 2025-11-19 Imperial College Innovations Limited Phage vector
CN116790521A (zh) * 2023-06-20 2023-09-22 扬州大学 一种可识别肿瘤表面的cea蛋白与表达egfp蛋白的重组噬菌体及其构建与应用
CN116790520A (zh) * 2023-06-20 2023-09-22 扬州大学 一种可识别肿瘤表面的cea蛋白与表达3c蛋白的短链噬菌粒及其构建与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
WO2005035714A2 (en) 2003-08-26 2005-04-21 Board Of Regents, The University Of Texas System Vaccines for cancer, autoimmune disease and infections
US8227242B2 (en) 2005-12-07 2012-07-24 Los Alamos National Security, Llc Plasmids and packaging cell lines for use in phage display
CN101460055A (zh) * 2006-04-07 2009-06-17 得克萨斯大学体系董事会 和腺伴随病毒-噬菌体颗粒相关的方法和组合物
CA2794196A1 (en) * 2010-03-23 2011-09-29 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
GB201308745D0 (en) 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
GB201308742D0 (en) 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
EP3092005B1 (en) * 2014-01-07 2019-05-22 Oklahoma Medical Research Foundation Antibodies against glioma biomarkers
SG11201802912PA (en) * 2015-10-10 2018-05-30 Intrexon Corp Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
GB201519303D0 (en) 2015-11-02 2015-12-16 Imp Innovations Ltd Phagemid vector
GB201706451D0 (en) 2017-04-24 2017-06-07 Imp Innovations Ltd Cancer treatment

Similar Documents

Publication Publication Date Title
JP2020517272A5 (https=)
CN105307671B (zh) 增强过继细胞疗法
US20220378822A1 (en) Combinatorial cancer immunotherapy
US11931409B2 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
JP2023524061A (ja) 操作された中枢神経系用組成物
Ruiz et al. MicroRNA-detargeted mengovirus for oncolytic virotherapy
JP2021518160A5 (https=)
JP2019501661A5 (https=)
EP4008333A1 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
JP2018533949A5 (https=)
US12071633B2 (en) Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
WO2018228538A1 (zh) 重组单纯疱疹病毒及其制备方法和应用
JP5943996B2 (ja) 腫瘍溶解性強化B型ヒトアデノウイルスAd11突然変異体の構築とその応用
US20200017881A1 (en) Programmable Oncolytic Virus Vaccine System and Method
CA3110282A1 (en) Fasl immunomodulatory gene therapy compositions and methods for use
JP2021500070A5 (https=)
CN102985094B (zh) 一种重组肿瘤疫苗及其生产方法
Kobelt et al. A brief introduction to current cancer gene therapy
CN120513099A (zh) 巨噬细胞特异性启动子和其用途
Goding et al. Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells
TW202448922A (zh) 改良之ert2突變體、可誘導型細胞死亡系統及其用途
CN112011570A (zh) 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用
CA3106093C (en) ANTI-TUMOR COMPOSITION
CN112823209A (zh) 使用编码高度紧凑的多输入逻辑门的核酸载体治疗疾病的方法
WO2026080028A1 (en) A phage-based gene delivery system producing predefined protein in host cells